Outperforming Biorecognition: Epitope-Imprinted Nanoparticle Enables High-Species-Specificity Purification of Human IgG
Source abstract
Abstract
Monoclonal antibodies are key therapeutics, but their purification remains costly and complex. Current industrial standards use biorecognition ligands such as protein A/G, which lack species-specificity. We report a highly species-selective nanoscale molecularly imprinted polymer (MIP) that enables the efficient purification of human IgG from complex samples, outperforming protein A/G in recognition performance. Unlike the “domain-to-domain” recognition for protein A/G, the “pocket-to-epitope” recognition mode endowed by our MIP enables precise differentiation of human IgG from IgGs of other species, which share a highly conserved structure. The MIP also exhibits “pit-one-against-four” performance, demonstrating high affinity toward all human IgG subclasses (with a K d value at the nM level). Moreover, owing to its excellent stability, the MIP allows for long-term storage at ambient temperature. Therefore, this study not only provides a new promising affinity nanomaterial for efficient antibody purification but also showcases the unique strength of MIPs to outperform biorecognition in terms of species-specificity.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · Analytical chemistry methods development · Biosensors and Analytical Detection
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, 163 Xianlin Avenue, Nanjing 210023, China
Funding
State Key Laboratory of Analytical Chemistry for Life Sciences · National Natural Science Foundation of China
References (53)
Show source-provided references
1. 10.1186/s13045-020-00876-410.1186/s13045-020-00876-4 ↗
2. 10.1038/nrd290910.1038/nrd2909 ↗
3. 10.1038/s41392-021-00868-x10.1038/s41392-021-00868-x ↗
4. Patil, R.; Shivarkar, A. Antibodies Drug Market Size, Trends and Regional Growth. Towards Healthcare , 2025. https://www.towardshealthcare.com/insights/antibodies-drug-market
5. 10.1016/j.seppur.2023.12382310.1016/j.seppur.2023.123823 ↗
6. 10.1007/s12247-018-09370-410.1007/s12247-018-09370-4 ↗
7. 10.1016/j.pep.2023.10631510.1016/j.pep.2023.106315 ↗
8. 10.1021/acs.jproteome.4c0026810.1021/acs.jproteome.4c00268 ↗
9. 10.1016/j.trac.2022.11674410.1016/j.trac.2022.116744 ↗
10. Bournazos S. · 2019 · 1
11. 10.1016/j.chroma.2024.46492910.1016/j.chroma.2024.464929 ↗
12. 10.1016/j.jim.2016.08.00510.1016/j.jim.2016.08.005 ↗
13. 10.1002/biot.20240025110.1002/biot.202400251 ↗
14. 10.1007/s00449-008-0295-410.1007/s00449-008-0295-4 ↗
15. 10.1016/j.pep.2005.01.01110.1016/j.pep.2005.01.011 ↗
16. 10.1016/S0022-1759(99)00195-710.1016/S0022-1759(99)00195-7 ↗
17. 10.1039/c2sc20125a10.1039/c2sc20125a ↗
18. 10.1038/nbt0298-19010.1038/nbt0298-190 ↗
19. 10.1021/acsami.4c1686110.1021/acsami.4c16861 ↗
20. 10.1080/0003271070165311110.1080/00032710701653111 ↗
21. 10.1002/anie.20100477410.1002/anie.201004774 ↗
22. 10.1002/anie.19951812110.1002/anie.199518121 ↗
23. 10.1038/361645a010.1038/361645a0 ↗
24. 10.1038/1926710.1038/19267 ↗
25. 10.1021/ja102148f10.1021/ja102148f ↗
26. 10.1002/anie.20120795010.1002/anie.201207950 ↗
27. 10.1002/anie.20150306610.1002/anie.201503066 ↗
28. 10.1038/nprot.2016.03010.1038/nprot.2016.030 ↗
29. 10.1039/C6CS00061D10.1039/C6CS00061D ↗
30. 10.1039/C7CS00854F10.1039/C7CS00854F ↗
31. 10.1038/nprot.2017.01510.1038/nprot.2017.015 ↗
32. 10.1016/j.eurpolymj.2023.11241110.1016/j.eurpolymj.2023.112411 ↗
33. 10.1016/j.procbio.2019.02.00110.1016/j.procbio.2019.02.001 ↗
34. 10.1016/j.chroma.2022.46291810.1016/j.chroma.2022.462918 ↗
35. 10.1016/j.jchromb.2019.05.02410.1016/j.jchromb.2019.05.024 ↗
36. 10.1002/advs.20220424610.1002/advs.202204246 ↗
37. 10.1021/jacs.8b1084810.1021/jacs.8b10848 ↗
38. 10.1016/S0021-9673(00)00568-910.1016/S0021-9673(00)00568-9 ↗
39. 10.1016/S0167-4838(00)00226-010.1016/S0167-4838(00)00226-0 ↗
40. 10.1002/anie.20050376010.1002/anie.200503760 ↗
41. 10.1002/advs.20210171310.1002/advs.202101713 ↗
42. 10.1039/C8SC04169E10.1039/C8SC04169E ↗
43. 10.1002/smll.20220645310.1002/smll.202206453 ↗
44. 10.1016/j.bios.2006.06.02310.1016/j.bios.2006.06.023 ↗
45. 10.1002/adma.20190204810.1002/adma.201902048 ↗
46. 10.1016/j.scib.2021.10.00610.1016/j.scib.2021.10.006 ↗
47. 10.1021/acsnano.4c1346310.1021/acsnano.4c13463 ↗
48. 10.1002/anie.20211352810.1002/anie.202113528 ↗
49. 10.1038/s41577-023-00871-z10.1038/s41577-023-00871-z ↗
50. 10.1093/intimm/13.12.155110.1093/intimm/13.12.1551 ↗
51. 10.1016/j.jchromb.2006.07.02010.1016/j.jchromb.2006.07.020 ↗
52. 10.1039/D2GC02686D10.1039/D2GC02686D ↗
53. 10.1016/j.jhazmat.2023.13112710.1016/j.jhazmat.2023.131127 ↗